Mammotome Expands Access to Innovative Breast Biopsy Site Marker

Securing this CE mark expands access to the HydroMARK™ Plus markers across Europe, combining proprietary hydrogel technology with features designed to support marker stability and visibility in breast care.

QUICKBORN, Germany, June 4, 2026 /PRNewswire/ -- Mammotome, a Danaher company and global leader in breast care innovation, has obtained a CE mark for the HydroMARK™ Plus Breast Biopsy Site Marker, scaling access to the innovative marker technology across Europe for patients undergoing breast cancer diagnosis and treatment.

Designed to enhance tissue adherence and help mitigate marker displacement during surgical excision, the HydroMARK™ Plus markers combine proprietary hydrogel technology with Wings that Cling™, which are exposed wing structures featured on the Dragonfly™ and Hummingbird™ marker shapes.1,2,3 The hydrogel carrier hydrates within 24 hours and is designed to provide ultrasound visibility for up to 12 months, including in patients undergoing neoadjuvant chemotherapy.⁴ Together, these features are intended to support accurate lesion localization.

The HydroMARK™ Plus markers are visible under ultrasound, mammography, and MRI, and are indicated for placement in breast tissue and lymph nodes.⁵"Mitigating the risk of surgical displacement is a priority for breast care teams as they guide patients through treatment," said Olaf Andrich, General Manager of EMEA at Mammotome. "The HydroMARK™ Plus markers were designed with a focus on marker stability and visibility, giving clinicians greater confidence that the marker will remain with the target tissue during surgery. Obtaining CE mark is an important step in expanding access to this technology across Europe."The HydroMARK™ Plus markers are part of the comprehensive breast biopsy site marker portfolio offered by Mammotome, providing physicians choice across a range of clinical needs. The HydroMARK™ Plus markers are FDA and Health Canada cleared and CE mark secured, reinforcing an ongoing commitment from Mammotome to expand access to advanced breast care technologies worldwide.